Results of treatment that combined iniparib with chemotherapy included extension of progression-free survival without increased side effects in patients with metastatic triple-negative breast cancer. These favorable results pave the way to the next step, Phase III clinical studies.
To learn more about the studies and where they will be conducted, see the article published online in the New England Journal of Medicine.
PARP Inhibition in Triple-Negative Breast Cancer.Joyce O’Shaughnessy, M.D., Cynthia Osborne, M.D., John E. Pippen, M.D., Mark Yoffe, M.D., Debra Patt, M.D., Christine Rocha, M.Sc., Ingrid Chou Koo, Ph.D., Barry M. Sherman, M.D., and Charles Bradley, Ph.D. 10.1056/NEJMoa1011418. January 5, 2011
5 6 7 8
© 2004-2011 Donna Peach. All rights reserved.